Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Angiotensin-(1-7) vs BPC-157 Arginate
An educational, source-based comparison of Angiotensin-(1-7) and BPC-157 Arginate — how each peptide works, what it's researched for, and what to know before going deeper.
Counter-regulatory peptide of the renin-angiotensin system.
A heptapeptide of the renin-angiotensin system that acts on Mas receptors. Research demonstrates counter-regulatory effects to angiotensin II, promoting vasodilation, anti-inflammatory signaling, and anti-fibrotic effects in cardiovascular and renal tissues.
- Pulmonary hypertension and fibrosis
- Heart failure with preserved ejection fraction
- Acute lung injury and ARDS
- Diabetic nephropathy
- • Investigational; not FDA-approved.
- • Interaction with ACE inhibitors and ARBs requires careful study design.
Stabilized salt form of BPC-157 with enhanced stability.
An arginate salt formulation of BPC-157 designed to improve stability and shelf-life. Research suggests the same angiogenic, anti-inflammatory, and tissue-repair mechanisms as standard BPC-157, with potentially improved bioavailability.
- Tendon and ligament healing
- Gastric ulcer protection
- Neuroprotection and nerve repair
- Systemic anti-inflammatory effects
- • Same cautions as standard BPC-157: preclinical data, not FDA-approved.
- • Quality of compounded formulations varies widely.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Angiotensin-(1-7) | Angiotensin-(1-7) as a therapeutic in lung disease | American Journal of Respiratory and Critical Care Medicine | 2020 | Demonstrated protective effects in acute lung injury and pulmonary fibrosis models. |
| Angiotensin-(1-7) | Mas receptor activation in cardiovascular protection | Circulation Research | 2018 | Reviewed anti-inflammatory and anti-fibrotic mechanisms in cardiac tissue. |
| BPC-157 Arginate | Stabilized BPC-157 formulations: comparative efficacy | Journal of Physiology and Pharmacology | 2020 | Arginate salt showed improved stability with equivalent tissue-repair activity. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Interaction with ACE inhibitors and ARBs requires careful study design.
- Same cautions as standard BPC-157: preclinical data, not FDA-approved.
- Quality of compounded formulations varies widely.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Angiotensin-(1-7) vs BPC-157 Arginate — Key differences
- Class: Angiotensin-(1-7) is classified as Cardiovascular · Anti-inflammatory, while BPC-157 Arginate is Tissue Repair · Gastrointestinal.
- Primary research focus: Angiotensin-(1-7) — pulmonary hypertension and fibrosis; BPC-157 Arginate — tendon and ligament healing.
- Tag: Cardiovascular · Anti-inflammatory vs Recovery.